Alexion Pharmaceuticals Inc., of Cheshire, Conn., said the National Institute for Health and Clinical Excellence Evaluation Committee acknowledged that FDA-approved Soliris (eculizumab) is an effective treatment option for patients with atypical hemolytic uremic syndrome, and that the use of eculizumab would be of significant value to patients with the life-threatening disorder who have no other treatment options.